“For example, in September 2013, FDA issued new labeling for long-acting and extended-release opioids, requiring that these drugs be used only for severe pain by patients needing continuous daily treatment over the long term and for whom alternative treatments are not adequate.”
Meet your new doctors: the DEA and the FDA.
All Things Chronic 